Distinct effects of dopamine vs STN stimulation therapies in associative learning and retention in Parkinson disease.
Identifieur interne : 000162 ( PubMed/Corpus ); précédent : 000161; suivant : 000163Distinct effects of dopamine vs STN stimulation therapies in associative learning and retention in Parkinson disease.
Auteurs : Jocelyne Ventre-Dominey ; Hélène Mollion ; Stephane Thobois ; Emmanuel BroussolleSource :
- Behavioural brain research [ 1872-7549 ] ; 2016.
English descriptors
- KwdEn :
- Adult, Aged, Association Learning (physiology), Deep Brain Stimulation, Disability Evaluation, Dopamine (metabolism), Dopamine Agents (therapeutic use), Female, Humans, Learning Disorders (etiology), Learning Disorders (therapy), Levodopa (therapeutic use), Male, Maze Learning (drug effects), Maze Learning (physiology), Middle Aged, Neuropsychological Tests, Parkinson Disease (complications), Photic Stimulation, Reaction Time (drug effects), Reaction Time (physiology), Retention (Psychology) (physiology), Subthalamic Nucleus (physiology), Time Factors.
- MESH :
- chemical , metabolism : Dopamine.
- complications : Parkinson Disease.
- drug effects : Maze Learning, Reaction Time.
- etiology : Learning Disorders.
- physiology : Association Learning, Maze Learning, Reaction Time, Retention (Psychology), Subthalamic Nucleus.
- chemical , therapeutic use : Dopamine Agents, Levodopa.
- therapy : Learning Disorders.
- Adult, Aged, Deep Brain Stimulation, Disability Evaluation, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Photic Stimulation, Time Factors.
Abstract
Evidence has been provided in Parkinson's disease patients of cognitive impairments including visual memory and learning which can be partially compensated by dopamine medication or subthalamic nucleus stimulation. The effects of these two therapies can differ according to the learning processes involving the dorsal vs ventral part of the striatum. Here we aimed to investigate and compare the outcomes of dopamine vs stimulation treatment in Parkinson patient's ability to acquire and maintain over successive days their performance in visual working memory. Parkinson patients performed conditional associative learning embedded in visual (spatial and non spatial) working memory tasks over two consecutive days either ON or OFF dopaminergic drugs or STN stimulation depending on the group of patients studied. While Parkinson patients were more accurate and faster in memory tasks ON vs OFF stimulation independent of the day of testing, performance in medicated patients differed depending on the medication status during the initial task acquisition. Patients who learnt the task ON medication the first day were able to maintain or even improve their memory performance both OFF and ON medication on the second day after consolidation. These effects were observed only in patients with dopamine replacement with or without motor fluctuations. This enhancement in memory performance after having learnt under dopamine medication and not under STN stimulation was mostly significant in visuo-spatial working memory tasks suggesting that dopamine replacement in the depleted dorsal striatum is essential for retention and consolidation of learnt skill.
DOI: 10.1016/j.bbr.2016.01.010
PubMed: 26778783
Links to Exploration step
pubmed:26778783Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Distinct effects of dopamine vs STN stimulation therapies in associative learning and retention in Parkinson disease.</title><author><name sortKey="Ventre Dominey, Jocelyne" sort="Ventre Dominey, Jocelyne" uniqKey="Ventre Dominey J" first="Jocelyne" last="Ventre-Dominey">Jocelyne Ventre-Dominey</name><affiliation><nlm:affiliation>INSERM Stem Cell and Brain Research Institute U846, Bron, France; Université Lyon 1, Lyon, France. Electronic address: Jocelyne.ventre-dominey@inserm.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Mollion, Helene" sort="Mollion, Helene" uniqKey="Mollion H" first="Hélène" last="Mollion">Hélène Mollion</name><affiliation><nlm:affiliation>Hospices Civils de Lyon, Hopital Neurologique, Centre Mémoire Ressources Recherche, Lyon, France; Université Lyon 1, Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Thobois, Stephane" sort="Thobois, Stephane" uniqKey="Thobois S" first="Stephane" last="Thobois">Stephane Thobois</name><affiliation><nlm:affiliation>Hospices Civils de Lyon, Hopital Neurologique, Neurologie C, Lyon, France; CNRS, Centre de Neurosciences Cognitives, UMR 5229, Bron, France; Université Lyon 1, Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Broussolle, Emmanuel" sort="Broussolle, Emmanuel" uniqKey="Broussolle E" first="Emmanuel" last="Broussolle">Emmanuel Broussolle</name><affiliation><nlm:affiliation>Hospices Civils de Lyon, Hopital Neurologique, Neurologie C, Lyon, France; CNRS, Centre de Neurosciences Cognitives, UMR 5229, Bron, France; Université Lyon 1, Lyon, France.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26778783</idno><idno type="pmid">26778783</idno><idno type="doi">10.1016/j.bbr.2016.01.010</idno><idno type="wicri:Area/PubMed/Corpus">000162</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000162</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Distinct effects of dopamine vs STN stimulation therapies in associative learning and retention in Parkinson disease.</title><author><name sortKey="Ventre Dominey, Jocelyne" sort="Ventre Dominey, Jocelyne" uniqKey="Ventre Dominey J" first="Jocelyne" last="Ventre-Dominey">Jocelyne Ventre-Dominey</name><affiliation><nlm:affiliation>INSERM Stem Cell and Brain Research Institute U846, Bron, France; Université Lyon 1, Lyon, France. Electronic address: Jocelyne.ventre-dominey@inserm.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Mollion, Helene" sort="Mollion, Helene" uniqKey="Mollion H" first="Hélène" last="Mollion">Hélène Mollion</name><affiliation><nlm:affiliation>Hospices Civils de Lyon, Hopital Neurologique, Centre Mémoire Ressources Recherche, Lyon, France; Université Lyon 1, Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Thobois, Stephane" sort="Thobois, Stephane" uniqKey="Thobois S" first="Stephane" last="Thobois">Stephane Thobois</name><affiliation><nlm:affiliation>Hospices Civils de Lyon, Hopital Neurologique, Neurologie C, Lyon, France; CNRS, Centre de Neurosciences Cognitives, UMR 5229, Bron, France; Université Lyon 1, Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Broussolle, Emmanuel" sort="Broussolle, Emmanuel" uniqKey="Broussolle E" first="Emmanuel" last="Broussolle">Emmanuel Broussolle</name><affiliation><nlm:affiliation>Hospices Civils de Lyon, Hopital Neurologique, Neurologie C, Lyon, France; CNRS, Centre de Neurosciences Cognitives, UMR 5229, Bron, France; Université Lyon 1, Lyon, France.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Behavioural brain research</title><idno type="eISSN">1872-7549</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Association Learning (physiology)</term><term>Deep Brain Stimulation</term><term>Disability Evaluation</term><term>Dopamine (metabolism)</term><term>Dopamine Agents (therapeutic use)</term><term>Female</term><term>Humans</term><term>Learning Disorders (etiology)</term><term>Learning Disorders (therapy)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Maze Learning (drug effects)</term><term>Maze Learning (physiology)</term><term>Middle Aged</term><term>Neuropsychological Tests</term><term>Parkinson Disease (complications)</term><term>Photic Stimulation</term><term>Reaction Time (drug effects)</term><term>Reaction Time (physiology)</term><term>Retention (Psychology) (physiology)</term><term>Subthalamic Nucleus (physiology)</term><term>Time Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Maze Learning</term><term>Reaction Time</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Learning Disorders</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Association Learning</term><term>Maze Learning</term><term>Reaction Time</term><term>Retention (Psychology)</term><term>Subthalamic Nucleus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Learning Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Deep Brain Stimulation</term><term>Disability Evaluation</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neuropsychological Tests</term><term>Photic Stimulation</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Evidence has been provided in Parkinson's disease patients of cognitive impairments including visual memory and learning which can be partially compensated by dopamine medication or subthalamic nucleus stimulation. The effects of these two therapies can differ according to the learning processes involving the dorsal vs ventral part of the striatum. Here we aimed to investigate and compare the outcomes of dopamine vs stimulation treatment in Parkinson patient's ability to acquire and maintain over successive days their performance in visual working memory. Parkinson patients performed conditional associative learning embedded in visual (spatial and non spatial) working memory tasks over two consecutive days either ON or OFF dopaminergic drugs or STN stimulation depending on the group of patients studied. While Parkinson patients were more accurate and faster in memory tasks ON vs OFF stimulation independent of the day of testing, performance in medicated patients differed depending on the medication status during the initial task acquisition. Patients who learnt the task ON medication the first day were able to maintain or even improve their memory performance both OFF and ON medication on the second day after consolidation. These effects were observed only in patients with dopamine replacement with or without motor fluctuations. This enhancement in memory performance after having learnt under dopamine medication and not under STN stimulation was mostly significant in visuo-spatial working memory tasks suggesting that dopamine replacement in the depleted dorsal striatum is essential for retention and consolidation of learnt skill.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26778783</PMID><DateCreated><Year>2016</Year><Month>02</Month><Day>26</Day></DateCreated><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7549</ISSN><JournalIssue CitedMedium="Internet"><Volume>302</Volume><PubDate><Year>2016</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Behavioural brain research</Title><ISOAbbreviation>Behav. Brain Res.</ISOAbbreviation></Journal><ArticleTitle>Distinct effects of dopamine vs STN stimulation therapies in associative learning and retention in Parkinson disease.</ArticleTitle><Pagination><MedlinePgn>131-41</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbr.2016.01.010</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0166-4328(16)30007-9</ELocationID><Abstract><AbstractText>Evidence has been provided in Parkinson's disease patients of cognitive impairments including visual memory and learning which can be partially compensated by dopamine medication or subthalamic nucleus stimulation. The effects of these two therapies can differ according to the learning processes involving the dorsal vs ventral part of the striatum. Here we aimed to investigate and compare the outcomes of dopamine vs stimulation treatment in Parkinson patient's ability to acquire and maintain over successive days their performance in visual working memory. Parkinson patients performed conditional associative learning embedded in visual (spatial and non spatial) working memory tasks over two consecutive days either ON or OFF dopaminergic drugs or STN stimulation depending on the group of patients studied. While Parkinson patients were more accurate and faster in memory tasks ON vs OFF stimulation independent of the day of testing, performance in medicated patients differed depending on the medication status during the initial task acquisition. Patients who learnt the task ON medication the first day were able to maintain or even improve their memory performance both OFF and ON medication on the second day after consolidation. These effects were observed only in patients with dopamine replacement with or without motor fluctuations. This enhancement in memory performance after having learnt under dopamine medication and not under STN stimulation was mostly significant in visuo-spatial working memory tasks suggesting that dopamine replacement in the depleted dorsal striatum is essential for retention and consolidation of learnt skill.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ventre-Dominey</LastName><ForeName>Jocelyne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>INSERM Stem Cell and Brain Research Institute U846, Bron, France; Université Lyon 1, Lyon, France. Electronic address: Jocelyne.ventre-dominey@inserm.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mollion</LastName><ForeName>Hélène</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Hospices Civils de Lyon, Hopital Neurologique, Centre Mémoire Ressources Recherche, Lyon, France; Université Lyon 1, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thobois</LastName><ForeName>Stephane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hospices Civils de Lyon, Hopital Neurologique, Neurologie C, Lyon, France; CNRS, Centre de Neurosciences Cognitives, UMR 5229, Bron, France; Université Lyon 1, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broussolle</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hospices Civils de Lyon, Hopital Neurologique, Neurologie C, Lyon, France; CNRS, Centre de Neurosciences Cognitives, UMR 5229, Bron, France; Université Lyon 1, Lyon, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>01</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Behav Brain Res</MedlineTA><NlmUniqueID>8004872</NlmUniqueID><ISSNLinking>0166-4328</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001245" MajorTopicYN="N">Association Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046690" MajorTopicYN="Y">Deep Brain Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="N">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015259" MajorTopicYN="N">Dopamine Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007859" MajorTopicYN="N">Learning Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010775" MajorTopicYN="N">Photic Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012153" MajorTopicYN="N">Retention (Psychology)</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020531" MajorTopicYN="N">Subthalamic Nucleus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Consolidation</Keyword><Keyword MajorTopicYN="N">Dopamine medication</Keyword><Keyword MajorTopicYN="N">Parkinson’s disease</Keyword><Keyword MajorTopicYN="N">STN stimulation</Keyword><Keyword MajorTopicYN="N">Visual working memory</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>08</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>01</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26778783</ArticleId><ArticleId IdType="pii">S0166-4328(16)30007-9</ArticleId><ArticleId IdType="doi">10.1016/j.bbr.2016.01.010</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000162 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000162 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26778783
|texte= Distinct effects of dopamine vs STN stimulation therapies in associative learning and retention in Parkinson disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26778783" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |